Acta Diabetologica最新文献

Background: Sarcopenia is a common condition in the elderly, especially in diabetics (DM). Metformin (MTF), known to reduce glucose levels, can also be a therapeutic intervention in age-related diseases, although it may contribute to muscle loss.

Objectives: To compare the prevalence of sarcopenia among elderly people treated for DM, with or without MTF, and non-diabetic patients (NDM) and evaluate whether there is an association between the use of MTF and the development of sarcopenia.

Methods: 194 independent elderly people over 80 years old were analyzed. Sarcopenia was defined by handgrip (HG), calf circumference (CC), and gait speed (GS). Non-parametric statistical analysis and Kaplan-Meier survival curves were used.

Results: The prevalence of DM was 24.7%, of which 56.25% used MTF. The median fasting blood glucose in the NDM and DM groups was 95 and 104 mg/dL. The median glycated hemoglobin in the NDM and DM groups was 5.7% and 6.4%. There was no statistical difference between the DM and NDM groups when comparing clinical characteristics, functionality, weight, physical tests, and mortality. The prevalence of sarcopenia was similar between NDM and DM (16.55% and 14.63%), with few cases of severe sarcopenia in both groups, without statistical differences. We did not find differences in the same variables when we analyzed NDM and DM using or not MTF. Survival curves showed no significant differences between patients with and without sarcopenia/severe sarcopenia.

Conclusions: Long-lived people with well-controlled DM did not show significant differences concerning those without DM for the outcome of sarcopenia or death.

Proper nutrition is essential during pregnancy to ensure an adequate supply of nutrients to the foetus and adequate maternal weight gain. In pregnancy complicated by diabetes (both gestational and pre-gestational), diet in terms of both the intake and quality of carbohydrates is an essential factor in glycaemic control. Maternal BMI at conception defines the correct weight increase during gestation in order to reduce maternal-foetal complications related to hypo- or hyper-nutrition. The recommendations presented here, which are based on national and international guidelines and the most recently published data on nutrition in physiological pregnancy and pregnancy complicated by hyperglycaemia and/or obesity, are designed to help healthcare professionals prescribe suitable eating patterns to safeguard the health of the mother and the foetus.

Introduction: Women with first trimester fasting glycaemia (FTFG) 92-125 mg/dL may present with normal 24-28th week OGTT (2T-OGTT). Predictors of persistent hyperglycaemia were scarcely investigated. We studied the prevalence and predictors of gestational diabetes mellitus (GDM) in the 2T-OGTT in women with untreated elevated FTFG.

Methods: Retrospective study of women from the national GDM registry with FTFG between 92 and 125 mg/dL that had passed unnoticed and untreated until the 2T-OGTT.

Primary endpoint: GDM in the 2T-OGTT. Women with and without GDM were compared. A multivariate logistic regression analysis was used to study GDM predictors. Included variables: FTFG, newborn sex, and known GDM risk factors.

Results: We studied 407 women. 82% (82.1%) of women had a positive 2T-OGTT. Women with abnormal 2T-OGTT were older, had higher BMI, and more often carried female newborns. There were no differences concerning other known GDM risk factors, FTFG, and obstetric or neonatal complications. Age, BMI and newborn sex were associated with higher risk of GDM independently of other GDM risk factors or FTFG. Per 1 year of age and 1 kg/m2 of BMI, the OR (95%CI) for this association were 1.10 (1.05-1.16) and 1.07 (1.02-1.12), respectively. Alternatively, women older than 35 years or with a BMI ≥ 30Kg/m2 had an OR of 2.53 (1.30-4.90) and 2.20 (1.22-3.98), respectively. Women with male newborns had approximately half the risk of abnormal 2T-OGTT [OR 0.51 (0.30-0.87)].

Conclusions: Nearly 18% of women with FTFG between 92 and 125 mg/dL had a normal 2T-OGTT. Older age, higher BMI, and female newborns were associated with increased risk of abnormal 2T-OGTT.

Aim: The outcomes of automated insulin delivery (AID) systems in pregnant women with type 1 diabetes (T1D) have not been systematically evaluated. This study aims to evaluate the efficacy and safety of AID in pregnancy.

Material and methods: Literature searches were conducted until July 5, 2024, on Embase, PubMed, Cochrane Library, and ClinicalTrials.gov website. We included clinical trials and observational studies evaluating AID systems in T1D pregnant individuals. Time in the target range (TIR, 3.5-7.8 mmol/L) was the primary outcome. Secondary outcomes included time below range (TBR, < 3.5 mmol/L), time above range (TAR, > 7.8 mmol/L), and maternal and neonatal outcomes.

Results: Eighteen studies (550 participants) were included. Compared with standard care, AID did not improve 24-h TIR (mean differences [MD] 3.56%, 95% CI - 0.60 to 7.72). However, the overnight TIR increased by 10.05% (95% CI 6.57 to 13.53). The association between AID and decreased TBR (MD - 0.90%, 95% CI - 1.60 to - 0.20) was found, but not with deceased TAR. Only 7 of the 17 studies achieved the goal of a 24-h TIR above 70%. Additionally, the maternal and neonatal outcomes were comparable between AID and standard care, and AID might reduce maternal weight gain (MD - 2.54 kg, 95% CI - 3.96 to - 1.11).

Conclusions: AID did not exhibit favourable TIR when compared to standard care. However, AID could increase overnight TIR and decrease TBR. Available evidence indicates that employing AID to meet the target of a 24-h TIR above 70% remains challenging.

Background: Gestational diabetes mellitus (GDM) is defined as a glucose intolerance resulting in hyperglycaemia of variable severity with onset during pregnancy, and is prevalent worldwide. The study of diagnostic markers of GDM in early pregnancy is important for early diagnosis and early intervention of GDM. The aim of this study was to search for biomarkers of GDM in early and mid-pregnancy using a targeted proteomics approach.

Methods: Through multiple response monitoring (MRM) technology and bioinformatics analysis including machine learning, 44 proteins associated with complement and coagulation cascades, and one protein, adiponectin, which is frequently reported to be associated with GDM, were targeted for quantitative analysis, and potential biomarkers were screened.

Results: The results showed that 7 and 6 proteins were identified as differentially expressed proteins (DEPs) between pregnant women subsequently diagnosed with GDM and controls during the first trimester, as well as between GDM cases and controls during the second trimester, respectively. Among them, C1QC and CFHR1 may serve as early predictive markers, and C1QC and adiponectin may serve as mid-term diagnostic markers.

Discussion: Complement and coagulation-related proteins and adiponectin, have been implicated in the pathogenesis of GDM, and some of these proteins have the potential to serve as markers for the prediction or diagnosis of GDM.

Aims: To assess the utility of reanalysing GCK variants of uncertain significance (VUS) as an intervention to improve the detection of monogenic diabetes.

Methods: We examined GCK VUS in a local cohort of individuals with suspected monogenic diabetes and re-curated each variant against the recent ClinGen GCK-specific variant classification guidelines.

Results: Variant reanalysis achieved a new 'likely pathogenic' classification (i.e., positive results) in 4/8 identified VUS. The single most common newly applied criterion indicating variant pathogenicity was a confirmed phenotype of GCK-hyperglycaemia. RNA sequencing and segregation studies were performed in two cases but not additive to reclassification.

Conclusions: This is the first VUS reclassification study in monogenic diabetes using gene-specific guidelines. Within the limits of this small study, we observed a high rate (50%) of VUS upgrades to a positive result, thereby confirming the utility of VUS reanalysis- particularly with biochemical phenotyping- in increasing the detection of monogenic diabetes. We recommend HbA1c, fasting blood glucose and either pancreatic autoantibody negativity or a small oral glucose tolerance test increment as a feasible minimum dataset to inform variant classification at the individual patient level, noting the ongoing work of the ClinGen Monogenic Diabetes Expert Panel in systematically reviewing GCK variants at the international level.